Quadrant Capital Group’s CASI Pharmaceuticals CASI Stock Holding History

Quadrant Capital Group’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-27	Closed	–	–	2513
2021 Q2	$0	Buy	+27	New	+$454	﹤0.01%	2420

Other funds holding CASI

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

IACGFIA

IDG-Accel China Growth Fund III Associates Hong Kong $31.2M AUM 2.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return

WSC

Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Quadrant Capital Group's CASI Position: Q3 2021 in Review

Quadrant Capital Group sold out of CASI Pharmaceuticals (CASI) in Q3 2021, closing a stake of 27 shares.

Quadrant Capital Group first reported a position in CASI in Q2 2021 and held it in 1 quarter. The position peaked at $0 in Q2 2021. 58 funds tracked by Wall St. Rank hold CASI as of Q3 2021.

Quadrant Capital Group reported no remaining CASI Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Quadrant Capital Group sold 27 CASI Pharmaceuticals shares in Q3 2021.
Quadrant Capital Group first reported a position in CASI Pharmaceuticals in Q2 2021 and held it in 1 quarter.
Quadrant Capital Group's CASI Pharmaceuticals position peaked at $0 in Q2 2021.
58 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q3 2021.

Based on Quadrant Capital Group's 13F filing for Q3 2021, filed 12 Nov 2021.